Biomarkers | Patients with adverse outcomes (n = 18) | Patients with favorable outcomes (n = 13) |
---|---|---|
IL-6 (pg mL−1) | 60.3 (29.1–121.1)* | 24.6 (3.9–45.0) |
IL-1β (pg mL−1) | 2.1 (2.0–2.2) | 2.3 (2.1–2.7) |
TNF-α (pg mL−1) | 17.7 (12.2–41.3) | 22.8 (15.7–31.9) |
NSE (μg L−1) | 0.52 (0.38–0.74) | 0.98 (0.44–2.13) |
S100B (ng mL−1) | 0.09 (0.06–0.12) | 0.11 (0.07–0.21) |
S100 (ng L−1) | 1.9 (0.4–15.8) | 3.5 (0.7–20.1) |
CKBB (ng mL−1) | 0.8 (0.6–1.5) | 1.0 (0.7–1.3) |
L/C ratio | 0.13 (0.04–0.26)* | 0.04 (0.03–0.06) |